Literature DB >> 2912935

Tumor bed effect-induced reduction of tumor radiocurability through the increase in hypoxic cell fraction.

L Milas1, N Hunter, L J Peters.   

Abstract

Two murine tumors, designated FSA and SA-NH, that exhibit strong tumor bed effect (TBE), were found to be less radiocurable if they grew in the preirradiated s.c. tissue. Tumors were transplanted into the right thighs irradiated with 30 Gy one day earlier, and were irradiated when they grew to 6 mm. The TBE-caused reduction in tumor radiocurability was manifested by the increase in TCD50 values. Tumor irradiation under hypoxic conditions increased TCD50 values less, and the hypoxic cell radiosensitizer misonidazole reduced TCD50 values more, when tumors grew in preirradiated than when they grew in unirradiated legs. This implies that TBE-induced increase in TCD50 was due to increase in hypoxic fraction of tumor cells. For 6 mm SA-NH tumor the estimated increase in hypoxic cell fraction was from the control value of 3% to 12%. Thus, TBE causes the reduction in tumor radiocurability through the increase in hypoxic fraction of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912935     DOI: 10.1016/0360-3016(89)90021-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cell Cycle       Date:  2009-04-04       Impact factor: 4.534

2.  Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation.

Authors:  C van Bree; E M Schopman; P J Bakker; J B Kipp; G W Barendsen
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin.

Authors:  J T Leith; G Papa; L Quaranto; S Michelson
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.